Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 21, 2014

NEW YORK (GenomeWeb News) – Rodney Markin has joined Trovagene's board of directors, and Chris McGuigan has resigned from the company's board to focus on other opportunities, Trovagene said this week.

Markin is chairman of Transgenomic, chief technology officer and associate vice chancellor for business development at the University of Nebraska Medical Center, and a professor of pathology and microbiology and surgery at the university.

Quest Diagnostics said this week it has shuffled two members of its senior leadership team and added one new member.

John Haydon will shift from his current post as senior VP of operations to a new role as VP of joint ventures and strategic programs. James Davis, formerly senior VP of diagnostic solutions, will succeed Haydon as senior VP of operations and will continue to oversee Quest's two product businesses, Focus Diagnostics and Celera Diagnostics.

The company also said Lidia Fonseca will become its new senior VP and chief information officer. She formerly was CIO at LabCorp and held senior leadership positions in supply chain and IT at Philips Healthcare.

Cancer Genetics has appointed Paul Rothman, dean of the medical faculty and CEO of Johns Hopkins Medicine, to serve on its board of directors.

Rothman oversees the Johns Hopkins Health System and the School of Medicine, and before that he was dean of the University of Iowa's Carver College of Medicine. He also formerly was head of internal medicine at UI and vice chairman for research and founding director of the Division of Pulmonary, Allergy and Critical Care at Columbia University College of Physicians.

Rosetta Genomics has appointed Kevin Watson to be director of reimbursement and managed care.

Watson joins Rosetta Genomics from bioTheranostics, where he was director of reimbursement. He formerly was president of GlobalPayer, a payer relations and reimbursement firm, and he spent six years in regional marketing and payer relations at Becton Dickinson Diagnostics – TriPath Imaging.

David Flannery, a pediatric geneticist, is the new medical director of the American College of Medical Genetics and Genomics.

Flannery is a founding fellow at ACMG, co-chair of its Economics of Genetic Services Committee, as well as a member of its Professional Practice and Guidelines Committee and CPT and Reimbursement Subcommittee. He also represents ACMG on the American Medical Association's CPT Advisory Committee.

Richard Leach has been elected to sit on Empirical Bioscience's board of directors.

Leach currently is VP of business development at Complete Genomics, a post he has held for three years, and he has over 18 years experience in the genome sequencing and personalized medicine fields. He also formerly was VP of Decode Genetics, founder and CSO at Teneo Biosciences, a senior field applications specialist at Affymetrix, and a scientist in the Division of Experimental Therapeutics at Walter Reed Army Institute of Research, as well as a visiting scientist at the National Cancer Institute.

Andy Watson has left RainDance Technologies. Watson was hired in May 2011 as chief marketing officer and most recently served as chief commercial officer of the company. Previously, he was vice president of advanced genetic systems for Life Technologies.

Opko Health has appointed Greg Stanley vice president of sales and marketing for its global diagnostics business unit.

Stanley was previously chief commercial officer of Oncimmune USA. Before that he was director of marketing and national director of corporate accounts for Roche Diagnostics.

Gentris has named Heath Knight as vice president of corporate development and Joseph Kessler as chief operating officer.

Knight was recently strategic director of companion diagnostics for LabCorp's Clinical Trials, and she was previously with Gentris as vice president of sales and marketing but had left in 2008 to join Third Wave Technologies, which was acquired by Hologic that year.

Kessler joins Gentris from DaVita labs, where he was senior director of laboratory operations and was responsible for oversight of their CAP/CLIA clinical testing laboratory and sample repository services. He also had worked for Merck Research Laboratories for 18 years.

Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.